Viking Therapeutics (VKTX) CFO Greg Zante Sells 21,217 Shares

What Happened

• Greg Zante, CFO of Viking Therapeutics (VKTX), had 31,667 performance-based restricted stock units vest on July 28, 2026 (no cash paid). On July 29, 2026 he sold 21,217 of those shares in the open market for total proceeds of about $710,141 (weighted average price $33.47). The remaining 10,450 vested shares were delivered to him after the sale to cover tax withholding.

Key Details

• Transaction dates: RSU vesting/acquisition 2026-07-28; sale 2026-07-29.
• Award: 31,667 performance RSUs vested (granted Jan 3, 2023; 33.33% vested on 7/28/26 after a non-financial performance goal was met) (Footnote F1).
• Sale details: 21,217 shares sold; weighted average price $33.47; prices ranged $33.30–$33.805 (Footnote F4). Proceeds ≈ $710,141.
• Tax withholding: The sold shares were automatically sold on a non‑discretionary basis solely to satisfy tax-withholding obligations related to the RSU vesting (Footnote F3).
• Prior holdings mentioned: filing notes 11,055 shares from the 2014 ESPP and 808 shares from the 2024 ESPP (Footnote F2). The filing does not present a single consolidated “shares owned after” number, but net shares retained from this vesting = 10,450.
• Filing timeliness: Report covers transactions through 2026-07-28 and was filed on 2026-07-29 (timely).

Context

• This was a vesting of performance RSUs followed by an automatic, tax-related sale of a portion of the vested shares — a routine administrative transaction rather than a voluntary discretionary sale for cash or diversification. Such withholding sales are common when restricted shares vest and do not by themselves signal the insider’s view on the company’s stock.